Here Come Earnings<br />By Rev Shark<br />RealMoney.com Contributor<br />1/14/2010 8:36 AM EST<br /><br /> Before everything else, getting ready is the secret to success.<br /> -- Henry Ford<br /><br />After eight days of trading, 2010 is looking much like 2009. We have had straight-up action on declining volume, aggressive dip-buying on very shallow pullbacks and quick recoveries just when it looked like we were ready to roll over. This very buoyant action on Wall Street in the face of a tepid economic recovery on Main Street confused many investors for much of 2009. Many are still confused by the strength of the market, but the sentiment polls now show that the pessimists have stopped fighting the trend and have largely capitulated.<br /><br />In fact, the most worrisome thing about this market is the very high level of complacency. There is very little fear that the market is going to pull back, and that makes for very dangerous conditions as quarterly earnings start to roll out. Now is the time to become mentally prepared for earnings season.<br /><br />The market acted well the last two quarters as earnings were reported, but the level of skepticism about the health of the economy was much higher six months ago. Investors were poorly positioned for strong earnings, and that's why we went almost straight up back in July when second-quarter earnings were reported.<br /><br />We had a positive reaction again in November as third-quarter earnings were reported, but the pace of the advance has slowed. We continue to wedge slowly higher on declining volume and we still have days like Wednesday when the bears are run over by the frisky buyers, but after a tremendous rally over the last nine months, the action is becoming more mixed.<br /><br />And that is the setup as Intel (INTC) and JPMorgan (JPM) kick off earnings season. Most of the important earnings reports will hit over the next two weeks, and they will determine the character of the market action. There have been few earnings warnings so far and the market seems to be quite optimistic that numbers will meet expectations, but we don't have much of a "wall of worry" to climb anymore and we're set up for a "sell the news" reaction.<br /><br />Intel has really set the stage for earnings season the last two quarters and will probably do so again tonight when it reports. Back in July, Intel surprised the market with a very strong report and drove everything straight up. In October, Intel surprised the market once again and gapped up initially but then traded down for several weeks. We had a number of stocks that were sold on good earnings news, but the broad market shrugged off those responses and continued to act well.<br /><br />We need to be ready for some very interesting action starting after the close today. This morning we have a little weakness on news reports that the Obama administration is ready to propose a "financial crisis responsibility fee" on some of the big banks. There are doubts that such a bill will pass the Senate, but it goes to show how politicians are pandering to populist anger about bonuses and the recent success on Wall Street.<br /><br />Plenty of stocks are acting well and the bears still look quite toothless, but earnings season can be full of land mines -- stay extremely nimble and vigilant as the news is digested.<br />-----------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: WSM +4.0%, SAP +3.2%, CVM +3.2%, ICLK +2.6% (light volume)... Select European drug names showing strength: SNY +1.3%, AZN +1.2%, SHPGY +1.1%... Other news: LAB +43.9% (announces agreement to sell NYSE designated market maker; redemption of all its outstanding indebtedness; authorization of stock repurchase), BNVI +24.2% (Announces Publication of "Positive Results" From the Phase 1B Clinical Trial of Bezielle for Metastatic Breast Cancer), EAG +11.1% (receives $9.8 mln in TACOM orders for crew protection kits, spare parts and field services), SNSS +11.1% (announces publication of nonclinical Voreloxin data in leukemias; studies demonstrate Voreloxin acts synergistically with cytarabine and induces bone marrow aplasia), CPBY +8.8% (reports Q4 contracts of ~$36.73 million), ETRM +7.4% (announces weight loss, hypertension and diabetes data from EMPOWER and ENABLE studies), JRJC +6.0% (still checking), HNSN +5.5% (Hansen Medical, Luna and Intuitive Surgical entered into a series of transactions), RNWK +3.6% (RealNetworks' founder Rob Glaser steps down as CEO), ARST +3.3% (Cramer makes positive comments on MadMoney), SQM +2.1% (Cramer makes positive comments on MadMoney), ORCL +1.8% (up in sympathy with SAP), FMBI +1.5% (prices ~16.4 million shares of common stock at $11.00 per share), CPTS +1.2% (light volume; profiled in New America section of IBD), DPZ +1.2% (Cramer makes positive comments on MadMoney)... Analyst comments: TSN +2.2% (upgraded to Outperform at Credit Suisse), PPG +1.5% (upgraded to Buy from Hold at Citigroup), BWLD +1.5% (upgraded to Buy at MKM Partners), MT +0.9% (upgraded to Outperform at Exane BNP Paribas).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: SEED -6.0%, CPKI -5.8%, BGG -4.0% (light volume), SMSI -3.6%... M&A news: DDRX -0.8% (Green Mountain Coffee Roasters and Diedrich Coffee receive requests for additional information from FTC)... Select oil/gas related names showing weakness: AMX -3.0%, PTR -2.1%, PBR -1.4%, BP -1.3%, TOT -1.1%... Other news: ROSG -28.8% (to raise $5.1 mln in registered direct offering), ATBC -26.8% (thinly traded; unit discloses it consented to the issuance of a Consent Order), MED -13.3% (securities litigation law firm is investigating potential violations of the federal securities laws by Medifast), CTIC -9.0% (announces institutional investors purchase $30 mln of preferred stock and warrants), ZLC -8.7% (announced that Neal Goldberg, Chief Executive Officer and member of the Board of Directors, have left the co effective immediately), SHAW -7.4% (still checking), KYN -6.7% (announces 5.5 mln common share public offering), PKX -2.5% (Goverment in overdrive to launch Posco plant - Economic Times), FPL -1.9% (halts capital expenditures in Florida; Credit Suisse discusses a rate case gone bad for FPL; tgt lowered to $56), MON -1.7% (has voluntarily cooperated with regulators to address their questions about its business and the broader agriculture industry)... Analyst comments: NFLX -3.6% (downgraded to Sell from Hold at Lazard Capital), TOL -1.9% (downgraded to Equal Weight at Barclays), CREE -1.4% (downgraded to Hold at Morgan Joseph), PCS -1.3% (downgraded to Neutral from Outperform at Macquarie), SSL -0.4% (downgraded to Underweight from Overweight at HSBC).